Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Valdemar Priebe
The BTK Inhibitor Zanubrutinib (BGB-3111) Demonstrated Synergies With Other Anti-Lymphoma Targeted Agents
Haematologica
Hematology
Related publications
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase
Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma
Community Oncology
Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma
Haematologica
Hematology
Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
A Head-To-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients With Waldenström Macroglobulinemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor
International Journal of Basic & Clinical Pharmacology
Copanlisib Synergies With Conventional and Targeted Agents Including Venetoclax in Preclinical Models of B- And T-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
